| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Wells Fargo analyst Tiago Fauth downgrades Inozyme Pharma (NASDAQ:INZY) from Overweight to Equal-Weight and announces $4 pri...
																	Jefferies analyst Ryan Deschner downgrades Inozyme Pharma (NASDAQ:INZY) from Buy to Hold and lowers the price target from $1...
																	
																	
																	Needham analyst Joseph Stringer downgrades Inozyme Pharma (NASDAQ:INZY) from Buy to Hold and maintains the price target from...
																	
																	
																	
																	Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Trea...